1-(叔丁氧基羰基)-6-甲氧基吲哚 | 138344-18-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 1-(叔丁氧基羰基)-6-甲氧基吲哚
• 英文名称: 1-(tert-butoxycarbonyl)-6-methoxyindole
• 英文别名: tert-butyl 6-methoxy-1H-indole-1-carboxylate；N-Boc-6-methoxyindole；tert-butyl 6-methoxyindole-1-carboxylate
• CAS: 138344-18-0
• 化学式: C₁₄H₁₇NO₃
• 分子量: 247.294
• InChiKey: OZWDNKUOSIOAPD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  40.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-BOC-6-Methoxyindole
Synonyms: t-Butyl 6-methoxy-1H-indole-1-carboxylate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-BOC-6-Methoxyindole
CAS number: 138344-18-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C14H17NO3
Molecular weight: 247.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(叔丁氧基羰基)-6-甲氧基吲哚 在 硼酸三异丙酯 、 lithium diisopropyl amide 、 盐酸 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 1-N-叔丁氧羰基-6-甲氧基吲哚-2-硼酸
  参考文献：
  名称：

  三恶唑啉/ Cu（II）催化的吲哚不对称分子内弗里德-克来夫茨烷基化反应

  摘要：

  描述了三恶唑啉/铜（II）催化的吲哚分子内Friedel-Crafts烷基化反应。这种成环法可轻松获得ee高达90％且产率高达99％的多环吲哚衍生物。

  DOI：

  10.1016/j.tet.2009.06.071
• 作为产物：
  描述：

  5-甲氧基-2-甲基苯胺 在 盐酸 、 仲丁基锂 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 为溶剂， 反应 1.66h， 生成 1-(叔丁氧基羰基)-6-甲氧基吲哚
  参考文献：
  名称：

  Preparation of Indoles and Oxindoles fromN-(tert-Butoxycarbonyl)-2-alkylanilines

  摘要：

  使用双锂化的N-(叔丁氧羰基)苯胺1与二甲基甲酰胺或二氧化碳反应，可得到中间体3和5，它们分别容易转化为N-(叔丁氧羰基)吲哚4和氧化吲哚（吲哚-2(3H)-酮，7）。双锂化的1与N-甲氧基-N-甲基酰胺缩合得到酮9，这些酮在三氟乙酸处理下环化，根据反应时间的不同，形成2-取代的1-(叔丁氧羰基)吲哚10或2-取代的吲哚11。这一通用方法已被应用于高效合成1,2-烷基桥联吲哚12、1,3,4,5-四氢苯[c,d]吲哚（16）、2a,3,4,5-四氢苯[c,d]吲哚-2(1H)-酮（18）以及1-(叔丁氧羰基)-1H-吡咯并[2,3-b]吡啶（21）。

  DOI：

  10.1055/s-1991-26597

文献信息

• Nickel-Catalyzed Dearomative Arylboration of Indoles: Regioselective Synthesis of C2- and C3-Borylated Indolines
  作者：Grace L. Trammel、Rositha Kuniyil、Phillip F. Crook、Peng Liu、M. Kevin Brown

  DOI：10.1021/jacs.1c05902

  日期：2021.10.13

  the C2- or C3-positions. Synthetically useful C2- and C3-borylated indolines can be accessed through a simple change in N-protecting group in high regio- and diastereoselectivities (up to >40:1 rr and >40:1 dr) from readily available starting materials. Additionally, the origin of regioselectivity was explored experimentally and computationally to uncover the remarkable interplay between carbonyl orientation

  吲哚脱芳构化是获取二氢吲哚的重要策略：二氢吲哚是存在于多种天然产物和生物活性分子中的基序。本文提出了一种过渡金属催化吲哚区域选择性脱芳香芳基硼化反应生成多种二氢吲哚的方法。该方法通过在 C2-或 C3-位置上缺乏激活或导向基团的底物上的迁移插入途径实现简单吲哚的分子间脱芳构化。合成有用的 C2- 和 C3- 硼酸化二氢吲哚可以通过简单改变N-保护基团以高区域选择性和非对映选择性（高达 >40:1 rr 和 >40:1 dr）从容易获得的起始材料获得。此外，通过实验和计算探索了区域选择性的起源，以揭示吲哚上N保护基团的羰基取向、C2-C3 π 键的电子和空间之间的显着相互作用。该方法首次实现了 (−)-azamedicarpin 的对映选择性合成。
• [EN] IMIDAZO-PYRIDINE COMPOUNDS AS PAD INHIBITORS<br/>[FR] COMPOSÉS IMIDAZO-PYRIDINE À UTILISER EN TANT QU'INHIBITEURS DE PAD
  申请人：JUBILANT BIOSYS LTD

  公开号：WO2019077631A1

  公开（公告）日：2019-04-25

  Heterocyclic compounds of Formula (I), (II), and (III) are described herein along with their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof. The compounds described herein, their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosis, cutaneous lupus erythematosis, ulcerative colitis, cancer, cystic fibrosis, asthma, multiple sclerosis and psoriasis. The process of preparation of the compounds of Formula (I), (II), and (III), their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof, along with a pharmaceutical composition comprising a compound of Formula (I), Formula (II), Formula (III), or a pharmaceutically acceptable salt thereof have also been described.

  公式（I）、（II）和（III）的杂环化合物以及它们的多晶形态、立体异构体、前药、溶剂合物、共晶体、中间体、药学上可接受的盐和代谢物在本文中被描述。本文描述的化合物、它们的多晶形态、立体异构体、前药、溶剂合物、共晶体、中间体、药学上可接受的盐和代谢物是PAD4抑制剂，可能在治疗各种疾病中有用，例如类风湿关节炎、血管炎、系统性红斑狼疮、皮肤红斑狼疮、溃疡性结肠炎、癌症、囊性纤维化、哮喘、多发性硬化和牛皮癣。还描述了制备公式（I）、（II）和（III）的化合物、它们的多晶形态、立体异构体、前药、溶剂合物、共晶体、中间体、药学上可接受的盐和代谢物的过程，以及包含公式（I）、公式（II）、公式（III）的化合物或其药学上可接受的盐的药物组合物。
• [EN] METHODS FOR TREATING HEPATITIS C<br/>[FR] PROCEDES POUR LE TRAITEMENT DE L'HEPATITE C
  申请人：PTC THERAPEUTICS INC

  公开号：WO2006019831A1

  公开（公告）日：2006-02-23

  In accordance with the present invention, compounds that inhibit viral replication, preferably Hepatitis C Virus (HCV) replication, have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the treatment or prevention of a viral infection are provided. In another aspect of the invention, compounds useful in the treatment or prevention of HCV infection are provided.

  根据本发明，已经确定了抑制病毒复制的化合物，优选是抑制丙型肝炎病毒（HCV）复制的化合物，并提供了它们的使用方法。在本发明的一个方面，提供了用于治疗或预防病毒感染的化合物。在本发明的另一个方面，提供了用于治疗或预防HCV感染的化合物。
• A sustainable C–H functionalization of indoles, pyrroles and furans under a blue LED with iodonium ylides
  作者：Saibal Sar、Ranajit Das、Dhiraj Barman、Pikaso Latua、Souvik Guha、Ludovic Gremaud、Subhabrata Sen

  DOI：10.1039/d1ob01219c

  日期：——

  Pyrrole and indole derivatives are functionalized via a green initiative with the dimethyl malonate derived phenyl iodonium ylide 4a in the presence of a blue LED via C–H functionalization of the respective heterocycles in methanol to generate the desired compounds 5–7 in moderate to good yields. Control experiments provide insight into the probable reaction mechanism. Finally, the strategy is successfully

  吡咯和吲哚衍生物通过绿色倡议与丙二酸二甲酯衍生的苯基碘鎓叶立德4a在蓝色 LED 存在下通过甲醇中各自杂环的 C-H 官能化进行官能化，以中等至良好的产率生成所需的化合物5-7 . 对照实验提供了对可能反应机制的深入了解。最后，该策略成功应用于azepino[4,5- b ]indole 12a / b的生成。
• Metal‐Free Oxidative Cross Coupling of Indoles with Electron‐Rich (Hetero)arenes
  作者：Paola Caramenti、Raj Kumar Nandi、Jerome Waser

  DOI：10.1002/chem.201802142

  日期：2018.7.17

  A new method for the synthesis of bi‐heteroaryls is reported, based on the umpolung of indoles with benziodoxol(on)e hypervalent iodine reagents (IndoleBX). The oxidative coupling of IndoleBX with an equimolar amount of electron‐rich benzenes, indoles, pyrroles, and thiophenes proceeded under mild transition‐metal‐free conditions. Functionalized non‐symmetrical bi‐indolyl heterocycles were accessed

  报道了一种合成双杂芳基的新方法，该方法基于吲哚与苯并碘醇 (on)e 高价碘试剂 (IndoleBX) 的 umpolung。IndoleBX 与等摩尔量的富电子苯、吲哚、吡咯和噻吩的氧化偶联在温和的无过渡金属条件下进行。有效地获得了功能化的非对称双吲哚基杂环。引入新型 C2 取代的吲哚苯并氧唑试剂进一步允许将反应范围扩展到 NH 未保护和 C3 烷基化吲哚。获得的双杂环是合成和药物化学中的重要组成部分，可以很容易地转化为更复杂的杂环系统。